Comparative Pharmacology
Head-to-head clinical analysis: AVELOX versus LEVAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVELOX versus LEVAQUIN.
AVELOX vs LEVAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
400 mg orally or intravenously once daily for 7 to 14 days depending on infection severity.
LEVAQUIN (levofloxacin) 500 mg orally or intravenously once daily for most infections; 750 mg orally or intravenously once daily for more severe infections or complicated urinary tract infections.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in healthy adults, allowing once-daily dosing. May be prolonged in patients with renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 48-108 hours in severe renal impairment (CrCl <20 mL/min).
Renal (approximately 45-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30% as unchanged drug and metabolites). Total recovery in urine and feces accounts for >96% of the dose.
Primarily renal excretion as unchanged drug (approximately 87% in urine); fecal excretion accounts for <5% as unchanged drug and metabolites; biliary excretion is minimal.
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)